The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
New strategies and perspectives on managing IgA nephropathy
Open accessAbstract
IgA nephropathy is an inflammatory renal disease characterised by the deposition of IgA in the glomerular mesangium and is the most commonly reported primary glomerulonephritis worldwide. Thirty to forty percent of patients with the disease develop progressive renal function decline, requiring renal replacement therapy within two decades of diagnosis. Despite this, accurate individual risk stratification at diagnosis and predicting treatment response remains a challenge. Furthermore, there are currently no disease specific treatments currently licensed to treat the condition due to long standing challenges in the nature and prevalence of the disease. Despite this, there have been exciting recent advances in the field that may represent paradigm shifts in the way IgA nephropathy is managed in the near future. In this review, we explore the evidence base informing current approaches to management and explore new strategies and future directions in the diagnosis and management of IgA nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are no commercially available disease-speci fi c therapies for IgA nephropathy, 4 in part because no largescale, randomized clinical trials have demonstrated a reduction in mortality or in major adverse kidney or cardiovascular events with any therapeutic intervention.”
From A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although IgA nephropathy is an immune-mediated disease, with mucosalderived IgA forming circulating immune complexes that deposit in the mesangium, 1 the role of immunosuppressive therapy remains controversial and is usually reserved for patients who do not respond to supportive measures.”
From A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Body Mass Index and Risk for End-Stage Renal Disease
Hsu, C.-Y., McCulloch, C. E., Iribarren, C., Darbinian, J., & Go, A. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-1-200601030-00006 · Cited by 1,390
Wyatt, R. J., & Julian, B. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206793 · Cited by 1,222
A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts, I. S. D., Cook, H. T., Troyanov, S., Alpers, C. E., Amore, A., Barratt, J., Berthoux, F., Bonsib, S., Bruijn, J. A., et al. (2009) · Kidney International · doi:10.1038/ki.2009.168 · Cited by 1,038
Self-citationROLE OF C5A IN INFLAMMATORY RESPONSES
Guo, R.-F., & Ward, P. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115835 · Cited by 1,021
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.9 · Cited by 966
The Pathophysiology of IgA Nephropathy
Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A. B., Renfrow, M. B., Wyatt, R. J., Scolari, F., Mestecky, J., Gharavi, A. G., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011050464 · Cited by 910
KDIGO Clinical Practice Guideline for Glomerulonephritis
Eckardt, K., & Kasiske, B. L. (2012) · Cited by 893
Research works printed but not linked: 1
- Edsbäcker S, Wollmer P, Nilsson A, Nillson M. Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules. Gastroenterology. 1993;104:A695.
Cited by
Wheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
Lv, J., Wong, M. G., Hladunewich, M. A., Jha, V., Hooi, L. S., Monaghan, H., Zhao, M., Barbour, S., Jardine, M. J., Reich, H. N., et al. (2022) · JAMA · doi:10.1001/jama.2022.5368 · Cited by 354
Metadata
- Authors
- Selvaskandan, H., Cheung, C. K., Muto, M., & Barratt, J.
- Affiliations
- University of Leicester (GB)
- Corresponding author
- Barratt, Jonathan
- Venue
- Clinical and Experimental Nephrology
- Published
- 2019-02-13
- Volume
- 23
- Issue
- 5
- Pages
- 577-588
- ISSN
- 1342-1751 (ISSN-L)
- 1437-7799
- PMC
- PMC6469670
- OpenAlex
- W2912114494
- Cited by
- 83
- References
- 110
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 16 · 2023: 14 · 2022: 24 · 2021: 14 · 2020: 9 · 2019: 1
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Clinical and Experimental Nephrology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research (CL-2016-11-002, ACF-2015-11-005)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- IgA nephropathy, primary glomerulonephritis, renal replacement therapy, risk stratification, treatment response prediction, disease management strategies, diagnosis
- MeSH terms
- Animals, Glomerulonephritis, IGA, Humans, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New strategies and perspectives on managing IgA nephropathy. https://app.cochat.ai/papers/10.1007/s10157-019-01700-1
- The paper
- Selvaskandan, H., Cheung, C. K., Muto, M., & Barratt, J. (2019). New strategies and perspectives on managing IgA nephropathy. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-019-01700-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.